Hepatic expression of CD36 is abnormally increased in non-alcoholic fatty liver disease, and a previous study indicated that hepatic CD36 upregulation was significantly associated with insulin resistance, hyperinsulinemia and increased steatosis in patients with NAFLD (22). This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.